NCT03085173View on ClinicalTrials.gov

"A Trial of Armored CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies"

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Chronic Lymphocytic Leukemia (CLL)RelapsedRefractory
Interventions
BIOLOGICAL

EGFRt/19-28z/4-1BBL CAR T cells

Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10\^5, 3 x 10\^5, 1 x 10\^6, and 3 x 10\^6 CAR T cells/kg.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER